Brokerages Expect UroGen Pharma Ltd. (NASDAQ:URGN) Will Post Earnings of -$1.26 Per Share

Equities research analysts expect UroGen Pharma Ltd. (NASDAQ:URGN) to announce earnings of ($1.26) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for UroGen Pharma’s earnings. The lowest EPS estimate is ($1.36) and the highest is ($1.10). UroGen Pharma reported earnings per share of ($1.31) during the same quarter last year, which indicates a positive year-over-year growth rate of 3.8%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 8th.

According to Zacks, analysts expect that UroGen Pharma will report full year earnings of ($4.90) per share for the current year, with EPS estimates ranging from ($5.11) to ($4.52). For the next financial year, analysts anticipate that the business will report earnings of ($3.29) per share, with EPS estimates ranging from ($4.28) to ($1.61). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover UroGen Pharma.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 4th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.07). UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. The business had revenue of $13.03 million during the quarter, compared to analyst estimates of $13.00 million.

Separately, Zacks Investment Research downgraded UroGen Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, July 20th.

URGN traded up $0.29 during trading on Friday, hitting $15.43. The company’s stock had a trading volume of 549 shares, compared to its average volume of 160,216. UroGen Pharma has a twelve month low of $14.19 and a twelve month high of $28.20. The stock’s fifty day moving average price is $15.73 and its 200-day moving average price is $17.39. The firm has a market capitalization of $322.49 million, a P/E ratio of -3.01 and a beta of 1.22.

A number of institutional investors and hedge funds have recently made changes to their positions in URGN. BNP Paribas Arbitrage SA raised its holdings in shares of UroGen Pharma by 17.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,439 shares of the company’s stock valued at $86,000 after acquiring an additional 657 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in UroGen Pharma by 21.1% in the first quarter. Public Employees Retirement System of Ohio now owns 6,900 shares of the company’s stock worth $134,000 after purchasing an additional 1,200 shares in the last quarter. Algert Global LLC purchased a new stake in shares of UroGen Pharma in the 1st quarter worth about $227,000. State Board of Administration of Florida Retirement System bought a new stake in shares of UroGen Pharma in the 2nd quarter worth $239,000. Finally, Wells Fargo & Company MN raised its position in UroGen Pharma by 368.3% in the 2nd quarter. Wells Fargo & Company MN now owns 19,916 shares of the company’s stock worth $304,000 after buying an additional 15,663 shares during the last quarter.

About UroGen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.

Further Reading: What is the Stochastic Momentum Index (SMI)?

Get a free copy of the Zacks research report on UroGen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.